Norway
· Delayed Price · Currency is NOK PCI Biotech Holding ASA Statistics
Total Valuation
PCI Biotech Holding ASA has a market cap or net worth of NOK 69.05 million. The enterprise value is 38.99 million.
| Market Cap | 69.05M |
| Enterprise Value | 38.99M |
Important Dates
The last earnings date was Wednesday, August 28, 2024.
| Earnings Date | Aug 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PCI Biotech Holding ASA has 37.33 million shares outstanding.
| Shares Outstanding | 37.33M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.76% |
| Owned by Institutions (%) | 13.82% |
| Float | 30.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.45 |
| EV / Sales | 6.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.86, with a Debt / Equity ratio of 1.49.
| Current Ratio | 6.86 |
| Quick Ratio | 6.86 |
| Debt / Equity | 1.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -174.46 |
Financial Efficiency
Return on equity (ROE) is -40.38% and return on invested capital (ROIC) is -27.85%.
| Return on Equity (ROE) | -40.38% |
| Return on Assets (ROA) | -24.73% |
| Return on Capital (ROIC) | -27.85% |
| Revenue Per Employee | 999,833 |
| Profits Per Employee | -2.65M |
| Employee Count | 6 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.15% in the last 52 weeks. The beta is 1.71, so PCI Biotech Holding ASA's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -4.15% |
| 50-Day Moving Average | 1.79 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 56.68 |
| Average Volume (20 Days) | 93,691 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PCI Biotech Holding ASA had revenue of NOK 6.00 million and -15.91 million in losses.
| Revenue | 6.00M |
| Gross Profit | 6.00M |
| Operating Income | -17.80M |
| Pretax Income | -15.91M |
| Net Income | -15.91M |
| EBITDA | -17.81M |
| EBIT | -17.80M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 30.54 million in cash and 475,000 in debt, giving a net cash position of 30.06 million or 0.81 per share.
| Cash & Cash Equivalents | 30.54M |
| Total Debt | 475,000 |
| Net Cash | 30.06M |
| Net Cash Per Share | 0.81 |
| Equity (Book Value) | 31.91M |
| Book Value Per Share | n/a |
| Working Capital | 31.56M |
Cash Flow
| Operating Cash Flow | -14.59M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of -296.63% and -265.24%.
| Gross Margin | 100.00% |
| Operating Margin | -296.63% |
| Pretax Margin | -265.24% |
| Profit Margin | -265.24% |
| EBITDA Margin | -296.92% |
| EBIT Margin | -296.63% |
| FCF Margin | n/a |
Dividends & Yields
PCI Biotech Holding ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |